What happens to the severity grading by objective SCORAD if we over- or underestimate disease extent or intensity in patients with atopic dermatitis?
- PMID: 22348565
- DOI: 10.1111/j.1365-4632.2011.05004.x
What happens to the severity grading by objective SCORAD if we over- or underestimate disease extent or intensity in patients with atopic dermatitis?
Abstract
Background: The objective SCORing Atopic Dermatitis (SCORAD) is a widely-used clinical score for assessing the extent, intensity, and severity of atopic dermatitis (AD).
Objective: We evaluated the effect on the severity grading if extent or intensity was under-estimated or overestimated.
Materials and methods: Six-hundred and fifty-one SCORADs performed over a 40-month period were evaluated. The effect on AD severity grading of six-hundred and fifty-one SCORADs performed over a 40-month period was evaluated if disease extent or intensivity was misestimated.
Results: The effect on AD grading was generally small if extent had been misestimated by 10% or 20%. In the mild grade (n=131), 40%, 62%, and 82% would have become moderate if the intensity had been underestimated by 1, 2, and 3, respectively. In the moderate grade (n=296), 13%, 27%, and 41% would have become severe if the intensity had been underestimated by 1, 2, and 3, respectively. The grading would have become mild in 16%, 31%, and 44% if the intensity had been overestimated by 1, 2, and 3, respectively. In the severe grade (n=224), 14%, 25%, and 38% would have become moderate if the intensity had been overestimated by 1, 2, and 3, respectively.
Conclusions: The effect on AD grading is generally small if extent is misestimated. A huge difference, especially if underestimated in the mild group, would occur if intensity is misestimated. Surrogate markers of disease severity could overcome or supplement shortcoming of clinical scores in AD research.
© 2012 The International Society of Dermatology.
Similar articles
-
Lesson from performing SCORADs in children with atopic dermatitis: subjective symptoms do not correlate well with disease extent or intensity.Int J Dermatol. 2006 Jun;45(6):728-30. doi: 10.1111/j.1365-4632.2005.02703.x. Int J Dermatol. 2006. PMID: 16796637
-
Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score.Br J Dermatol. 2007 Oct;157(4):645-8. doi: 10.1111/j.1365-2133.2007.08112.x. Epub 2007 Aug 21. Br J Dermatol. 2007. PMID: 17714568 Review.
-
Urinary leukotriene E4 correlates with severity of atopic dermatitis in children.Clin Exp Dermatol. 2004 May;29(3):277-81. doi: 10.1111/j.1365-2230.2004.01512.x. Clin Exp Dermatol. 2004. PMID: 15115511
-
The Atopic Dermatitis Quickscore (ADQ): validation of a new parent-administered atopic dermatitis scoring tool.Ann Allergy Asthma Immunol. 2008 Nov;101(5):500-7. doi: 10.1016/S1081-1206(10)60289-X. Ann Allergy Asthma Immunol. 2008. PMID: 19055204
-
A practical overview of pediatric atopic dermatitis, part 2: triggers and grading.Cutis. 2016 May;97(5):326-9. Cutis. 2016. PMID: 27274543 Review.
Cited by
-
A Microbiome-Based Index for Assessing Skin Health and Treatment Effects for Atopic Dermatitis in Children.mSystems. 2019 Aug 20;4(4):e00293-19. doi: 10.1128/mSystems.00293-19. mSystems. 2019. PMID: 31431508 Free PMC article.
-
Development and initial validation of a Traditional Chinese Medicine symptom-specific outcome measure: a Zheng-related atopic dermatitis symptom questionnaire (ZRADSQ).Health Qual Life Outcomes. 2013 Dec 21;11:212. doi: 10.1186/1477-7525-11-212. Health Qual Life Outcomes. 2013. PMID: 24359229 Free PMC article.
-
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources